Advertisement

Inflammopharmacology

, Volume 23, Issue 2–3, pp 71–77 | Cite as

Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs

  • Sandhya JineshEmail author
Review

Abstract

Tumor necrosis factor (TNF) is a key regulator of inflammatory processes in several immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis. Inactivating TNF has been found to be a plausible approach in treating these conditions. Two major strategies have been adopted by scientists to inactivate TNF: one is to use monoclonal antibodies (mAbs) that bind to TNF, and the other is to use fusion proteins that bind to TNF, both inactivate TNF and help to prevent TNF-mediated inflammatory processes. Monoclonal antibodies (mAbs) are biological products that selectively bind to specific antigen molecules, and fusion proteins are soluble receptors that bind to TNF. These types of drugs are generally known as biologics and there has been an explosion in the development and testing of biologics since the 1994 US approval and launch of abciximab, a mAb that binds to GPIIb/IIIa on platelets. Anti-TNF drugs that are currently approved by FDA for treating inflammatory conditions include adalimumab, certolizumab pegol, golimumab, infliximab and etanercept. Since these agents are complex protein molecules, the pharmacodynamics and pharmacokinetics of these drugs are different from small-molecule anti-inflammatory agents. This review focuses on the pharmaceutical aspects of these drugs such as mechanism of action, adverse effects, pharmacokinetics and drug interactions. An effort was also taken to compare the pharmacodynamics and pharmacokinetic properties of these drugs, with the available data at this time.

Keywords

TNF inhibitors Monoclonal antibodies mAb Adalimumab Certolizumab pegol Golimumab Infliximab and etanercept 

References

  1. Aaltonen KJ, Virkki LM, Malmivaara A et al (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7(1):e30275 pub 2012 Jan 17CrossRefPubMedCentralPubMedGoogle Scholar
  2. Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315CrossRefPubMedGoogle Scholar
  3. Arenzana-Seisdedos F, Teyton L, Virelizier JL (1987) Immunoregulatory mediators in the pathogenesis of rheumatoid arthritis. Scand J Rheumatol Suppl 66:13–17CrossRefPubMedGoogle Scholar
  4. Armuzzi A, Lionetti P, Blandizzi C et al (2014) Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27(1 Suppl):11–32PubMedGoogle Scholar
  5. Behrens F, Cañete JD, Olivieri I et al (2014) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford). pii: keu415. [Epub ahead of print]Google Scholar
  6. Boyce EG, Halilovic J, Stan-Ugbene O (2010) Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Clin Ther 32:1681–1703CrossRefPubMedGoogle Scholar
  7. Braun J, Sieper J (2003) Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 3:141–168CrossRefPubMedGoogle Scholar
  8. Brennan FM et al (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 29:244–247CrossRefGoogle Scholar
  9. Brennan FR, Morton LD, Sebastian Spindeldreher S et al (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2:233–255CrossRefPubMedCentralPubMedGoogle Scholar
  10. Bringman TS, Aggarwal BB (1987) Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma 6:489–507CrossRefPubMedGoogle Scholar
  11. Cassinotti A, Ardizzone S, Porro BG (2007) Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease. Core Evid 2:209–229PubMedCentralGoogle Scholar
  12. Choi C, Kim T, Park H et al (2008) Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci 23:852–856CrossRefPubMedCentralPubMedGoogle Scholar
  13. Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104–111CrossRefPubMedCentralPubMedGoogle Scholar
  14. Dostalek M, Gardner I, Gurbaxani BM et al (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83–124CrossRefPubMedGoogle Scholar
  15. Elliott MJ, Maini RN, Feldmann M et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:681–690CrossRefGoogle Scholar
  16. Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110CrossRefPubMedGoogle Scholar
  17. Fallahi-Sichani M, Flynn JL, Linderman JJ et al (2012) Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 188:3169–3178CrossRefPubMedCentralPubMedGoogle Scholar
  18. FDA (2009) Cancer warnings required for TNF blockers. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm. Accessed on 19 Jan 2015
  19. FDA Drug Safety Communication (2011) Drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm. Accessed on 19 Jan 2015
  20. Ferrajoli A, Talpaz M, Kurzrock R et al (1993) Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells 11:112–119CrossRefPubMedGoogle Scholar
  21. Gottlieb AB (2007) Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 12:1–4CrossRefPubMedGoogle Scholar
  22. Hirai M, Okamura N, Terano Y et al (1987) Production and characterization of monoclonal antibodies to human tumor necrosis factor. J Immunol Methods 96:57–62CrossRefPubMedGoogle Scholar
  23. Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 12:1558–1565CrossRefGoogle Scholar
  24. Jackson JM (2007) TNF- alpha inhibitors. Dermatol Ther 20:251–264CrossRefPubMedGoogle Scholar
  25. Keffer J et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031PubMedCentralPubMedGoogle Scholar
  26. Kievit W, Fransen J, Oerlemans AJ et al (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66:1473–1478CrossRefPubMedCentralPubMedGoogle Scholar
  27. Kirman I, Whelan RL, Nielsen OH (2004) Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16:639–641CrossRefPubMedGoogle Scholar
  28. Knight DM et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453CrossRefPubMedGoogle Scholar
  29. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497CrossRefPubMedGoogle Scholar
  30. Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online, Hudson, Ohio: Lexi-Comp, Inc. (2014)Google Scholar
  31. Machado MA, Barbosa MM, Almeida AM et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199–2213CrossRefPubMedGoogle Scholar
  32. Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341–1359CrossRefPubMedGoogle Scholar
  33. Meager A, Parti S, Leung H et al (1987) Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 6:305–311CrossRefPubMedGoogle Scholar
  34. Mewar D, Wilson AG (2011) Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 162:785–791CrossRefPubMedCentralPubMedGoogle Scholar
  35. Michaud TL, Rho YH, Shamliyan T et al (2014) The comparative safety of TNF Inhibitors in rheumatoid arthritis—a meta-analysis update of 44 randomized controlled trials. Am J Med. doi: 10.1016/j.amjmed.2014.06.012 [Epub ahead of print]PubMedGoogle Scholar
  36. Mohler KM, Torrance DS, Smith CA et al (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561PubMedGoogle Scholar
  37. Movat HZ, Cybulsky MI, Colditz IG et al (1987) Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc 46:97–104PubMedGoogle Scholar
  38. Nam JL, Winthrop KL, van Vollenhoven RF et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976–986CrossRefPubMedGoogle Scholar
  39. Neovius M, Arkema EV, Olsson H et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74:354–360CrossRefPubMedCentralPubMedGoogle Scholar
  40. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34((5 Suppl1)):12–18CrossRefPubMedGoogle Scholar
  41. Ordás I, Feagan BG, Sandborn WJ (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10:1079–1087CrossRefPubMedGoogle Scholar
  42. Raja H, Matteson EL, Michet CJ et al (2012) Safety of tumor necrosis factor inhibitors during pregnancy and breastfeeding. Transl Vis Sci Technol 2012(1):6CrossRefGoogle Scholar
  43. Rau R (2010) Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol 28:S58–S64PubMedGoogle Scholar
  44. Raza A (2000) Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 50:229–235CrossRefPubMedGoogle Scholar
  45. Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784CrossRefPubMedGoogle Scholar
  46. Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547–549CrossRefPubMedGoogle Scholar
  47. Saxne T et al (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041–1045CrossRefPubMedGoogle Scholar
  48. Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factor alpha. J Exp Med 167:1511–1516CrossRefPubMedGoogle Scholar
  49. Spadiut O, Capone S, Krainer F et al (2013) Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 32:54–60CrossRefPubMedGoogle Scholar
  50. Thorbecke GJ et al (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci 89:7375–7379CrossRefPubMedCentralPubMedGoogle Scholar
  51. Tracey D, Klareskog L, Eric H et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279CrossRefPubMedGoogle Scholar
  52. Trehu EG, Mier JW, Dubois JS et al (1996) Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 2:1341–1351PubMedGoogle Scholar
  53. Wallis RS (2007) Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 12:16–21CrossRefPubMedGoogle Scholar
  54. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci 89:9784–9788CrossRefPubMedCentralPubMedGoogle Scholar
  55. Wong M, Ziring D, Korin Y, Desai S et al (2009) TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 126:121–136CrossRefGoogle Scholar
  56. Xixi MA, Shengqian XU (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:177–184Google Scholar

Copyright information

© Springer Basel 2015

Authors and Affiliations

  1. 1.West Haven PharmacyWest HavenUSA

Personalised recommendations